Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CP-866087
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CP-866087 is a small molecule drug developed by Pfizer as a selective mu opioid receptor antagonist. It was investigated in clinical trials for the treatment of obesity, alcoholism, and female sexual arousal disorder (FSAD). Preclinical studies showed that it could antagonize morphine effects and reduce alcohol intake in animal models. In human trials, although some improvements were observed on efficacy endpoints for FSAD, there was no significant clinical benefit over placebo. The compound reached phase II development but has since been discontinued for all known indications[1][2][6][9].
- Other names
- 519052-02-9UNII-MDH21334PIUNII-MDH-21334PIUNII-MDH 21334PI
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on CP-866087.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CP-866087.